Regardless of the underlying molecular mechanisms, if it will be confirmed, the observed relation between the expression levels of cyclin E and cell sensitivity to doxorubicin might have important implications for the treatment of cancer, mainly breast cancer patients. This evidence concerns the gene CCNE1 and breast carcinoma.